TABLE 2.

Multivariate Cox Regression Analysis for Ischemic vs Nonischemic Patients With Heart Failure

	Ischemic etiology		Nonischemic etiology		All patients
Characteristic	Cox HR (95% CI)	P value	Cox HR (95% CI)	P value	Cox HR (95% CI)	P value
Age	1.04 (1.02-1.05)	<.001	1.03 (1.01-1.05)	.003	1.03 (1.02-1.05)	<.001
Female	0.79 (0.55-1.15)	.23	0.61 (0.41-0.91)	.02	0.72 (0.55-0.93)	.01
NYHA	1.23 (0.97-1.57)	.09	1.53 (1.16-2.01)	.003	1.36 (1.14-1.63)	.001
LVEF	0.99 (0.98-1.00)	.04	0.99 (0.99-1.01)	.62	0.99 (0.98-0.99)	.02
Diabetes	1.98 (1.51-2.59)	<.001	1.02 (0.69-1.51)	.91	1.50 (1.22-1.85)	<.001
Cholest	1.00 (0.99-1.00)	.78	0.99 (0.99-1.00)	.05	0.99 (0.99-1.00)	.17
COPD	1.05 (0.75-1.46)	.79	1.21 (0.82-1.79)	.34	1.18 (0.92-1.49)	.19
PVD	1.71 (1.26-2.31)	.001	1.59 (0.98-2.59)	.06	1.62 (1.26-2.09)	<.001
BMI	1.04 (1.01-1.08)	.02	0.96 (0.92-0.99)	.03	0.99 (0.97-1.02)	.83
Hb	0.96 (0.88-1.05)	.41	0.93 (0.85-1.03)	.15	0.95 (0.89-1.01)	.13
CrCl	0.99 (0.98-0.99)	.004	0.99 (0.99-1.01)	.76	0.99 (0.99-0.99)	.03
HF t	1.00 (0.99-1.01)	.26	1.00 (1.00-1.01)	.03	1.00 (1.00-1.00)	.006
AF	1.07 (0.66-1.74)	.78	1.08 (0.72-1.61)	.71	0.99 (0.74-1.34)	.98
Statins	0.66 (0.49-0.89)	.007	0.54 (0.37-0.79)	.002	0.66 (0.53-0.83)	<.001
ACEI/ARB	0.52 (0.36-0.76)	.001	0.61 (0.37-1.00)	.05	0.52 (0.39-0.69)	<.001
β-Blockers	0.38 (0.26-0.55)	<.001	0.57 (0.39-0.84)	.004	0.51 (0.39-0.66)	<.001
Antipl	0.73 (0.51-1.05)	.09	0.77 (0.54-1.11)	.16	0.85 (0.67-1.07)	.16
ICD	0.71 (0.42-1.18)	.19	0.76 (0.33-1.78)	.53	0.77 (0.49-1.18)	.23

ACEI = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; Antipl = antiplatelet therapy; ARB = angiotensin receptor blocker; BMI = body mass index; Cholest = cholesterol; CI = confidence interval; COPD = chronic obstructive pulmonary disease; CrCl = creatinine clearance; Hb = hemoglobin; HF t = heart failure duration from onset; HR = hazard ratio; ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PVD = peripheral vascular disease.